DOCSLIB.ORG

Download Brand to Generic Cross Reference

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download Brand to Generic Cross Reference HENRY SCHEIN GENERIC PORTFOLIO GENERIC TO BRAND CROSS REFERENCE ALPHA ORDER: GENERIC DESCRIPTION ALL PRODUCTS: as of 2/1/16 SCHEIN CONTR RX, ITEM GENERIC DESCRIPTION STRENGTH SIZE DRUG OTC, SUPPLIER NAME NDC BRAND COMPARE TO MAJOR SPECIALTY INDICATION NUMBER CLASS INJ 1027053 ABC PLUS MULTI W/LUTEIN TABLETS 100/BT OTC US NUTRITION 74312-4178-32 VITAMINS/NUTRITIONALS HBA VITAMINS VITAMIN DEFICIENCY 1049698 ABC PLUS SENIOR TABLETS 60/BT OTC US NUTRITION VITAMINS/NUTRITIONALS HBA VITAMINS VITAMIN DEFICIENCY 1200797 ACETAMINOPHEN CAPLETS 500MG 100/BT OTC NEW WORLD IMPORTS 51824-0012-01 TYLENOL CAPLETS HBA ANALGESIC 1194282 ACETAMINOPHEN CAPLETS 500MG 1000/BT OTC PLUS PHARMA 51645-0705-10 TYLENOL CAPLETS HBA ANALGESIC 1233463 ACETAMINOPHEN CAPLETS 500MG 50/BT OTC CARDINAL 00904-1983-51 TYLENOL CAPLETS HBA ANALGESIC 1244649 ACETAMINOPHEN CHEWABLE TABLETS FRUIT 80MG 30/BT OTC RELIABLE 1 69618-0012-03 TYLENOL CHILDRENS HBA ANALGESIC 1108964 ACETAMINOPHEN GELCAPS 500MG 100/BT OTC GERI-CARE 57896-0251-01 TYLENOL XS GELCAPS HBA ANALGESIC 1023072 ACETAMINOPHEN ORAL DROPS INFANT 80MG/0.8ML 15ML/BT OTC LANNETT 54838-0145-15 TYLENOL DROPS HBA ANALGESIC 1229783 ACETAMINOPHEN ORAL ELIXIR 160MG/5ML 4OZ/BT OTC MAJOR PHARM 00904-1985-00 TYLENOL ELIXIR HBA ANALGESIC 2770123 ACETAMINOPHEN ORAL ELIXIR 160MG/5ML 16OZ/BT OTC CARDINAL 00904-1985-16 TYLENOL ELIXIR HBA ANALGESIC 4080290 ACETAMINOPHEN ORAL ELIXER PEDIATRIC 160MG/5ML 120ML/BT OTC LANNETT 54838-0144-40 TYLENOL PED LIQUID HBA ANALGESIC 1158484 ACETAMINOPHEN ORAL SOLUTION 160MG/5ML 16OZ/BT OTC GERI-CARE 57896-0109-16 TYLENOL LIQUID HBA ANALGESIC 1239321 ACETAMINOPHEN ORAL SOLUTION 5ML UD 160MG/5ML 100/CA OTC CARDINAL 00121-0657-05 TYLENOL LIQUID HBA ANALGESIC 1174288 ACETAMINOPHEN ORAL SOLUTION 10ML UD 160MG/5ML 100/CA OTC PAI 00121-0657-11 TYLENOL LIQUID HBA ANALGESIC 1242730 ACETAMINOPHEN ORAL SUSPENSION 160MG/5ML 2OZ/BT OTC CARDINAL 00536-3606-96 TYLENOL PED LIQUID HBA ANALGESIC 1229694 ACETAMINOPHEN PED RAPID TABLETS 160MG 24/BT OTC MAJOR PHARM 00904-5754-24 TYLENOL PED RAPID TABS HBA ANALGESIC 1229716 ACETAMINOPHEN PED RAPID TABLETS 80MG 30/BT OTC MAJOR PHARM 00904-5751-46 TYLENOL PED RAPID TABS HBA ANALGESIC 1200790 ACETAMINOPHEN PM CAPLETS 500MG 50/BT OTC NEW WORLD IMPORTS 51824-0015-05 TYLENOL PM CAPLETS XS HBA ANALGESIC 1222650 ACETAMINOPHEN SUPPOSITORIES ADULT 325MG 6/BX OTC TARO 51672-2116-02 TYLENOL SUPP HBA ANALGESIC 2770107 ACETAMINOPHEN SUPPOSITORIES ADULT 325MG 12/BX OTC CARDINAL 00713-0164-12 TYLENOL SUPP HBA ANALGESIC 2770120 ACETAMINOPHEN SUPPOSITORIES ADULT 325MG 50/BX OTC CARDINAL 00713-0164-50 TYLENOL SUPP HBA ANALGESIC 4724812 ACETAMINOPHEN SUPPOSITORIES ADULT 650MG 12/BX OTC PERRIGO PHARM 45802-0730-30 TYLENOL SUPP HBA ANALGESIC 1084619 ACETAMINOPHEN SUPPOSITORIES ADULT 650MG 50/BX OTC PERRIGO PHARM 45802-0730-32 TYLENOL SUPP HBA ANALGESIC 4724712 ACETAMINOPHEN SUPPOSITORIES PEDIATRIC 120MG 12/BX OTC PERRIGO PHARM 45802-0732-30 TYLENOL SUPP HBA ANALGESIC 1088998 ACETAMINOPHEN SUPPOSITORIES PEDIATRIC 120MG 100/BX OTC PERRIGO PHARM 45802-0732-33 TYLENOL SUPP HBA ANALGESIC 1241928 ACETAMINOPHEN TABLETS 325MG 100/BT OTC NEW WORLD IMPORTS 51824-0010-01 TYLENOL TABS HBA ANALGESIC 1196829 ACETAMINOPHEN TABLETS 325MG 1000/BT OTC PLUS PHARMA 51645-0703-10 TYLENOL TABS HBA ANALGESIC 1234162 ACETAMINOPHEN TABLETS 325MG 50/BT OTC CARDINAL 57896-0101-05 TYLENOL TABS HBA ANALGESIC 9004689 ACETAMINOPHEN TABLETS UD 325MG 125x2/PK OTC HENRY SCHEIN 00404-0714-13 TYLENOL TABS HBA ANALGESIC 1006861 ACETAMINOPHEN TABLETS UD 325MG 250x2/PK OTC MEDIQ 47682-0145-13 TYLENOL TABS HBA ANALGESIC 1229658 ACETAMINOPHEN TABLETS UD 325MG 100/PK OTC MAJOR PHARM 00904-1982-61 TYLENOL TABS HBA ANALGESIC 1200794 ACETAMINOPHEN TABLETS X-STRENGTH 500MG 100/BT OTC NEW WORLD IMPORTS 51824-0011-01 TYLENOL TABS HBA ANALGESIC 1194355 ACETAMINOPHEN TABLETS X-STRENGTH 500MG 1000/BT OTC PLUS PHARMA 51645-0706-10 TYLENOL TABS HBA ANALGESIC 1229669 ACETAMINOPHEN TABLETS X-STRENGTH UD 500MG 100/PK OTC MAJOR PHARM 00904-1988-61 TYLENOL TABS HBA ANALGESIC 9004690 ACETAMINOPHEN TABLETS X-STRENGTH UD 500MG 250x2/PK OTC HENRY SCHEIN 00404-0716-13 TYLENOL XS TABS HBA ANALGESIC 2770449 ACETAZOLAMIDE ER CAPSULES 500MG 100/BT RX CARDINAL 23155-0120-01 DIAMOX SEQUELS CARDIOVASCULAR ANTIHYPERTENSIVE 2770416 ACETAZOLAMIDE ER CAPSULES UD BLISTERPACK 500MG 30/BX RX CARDINAL 68084-0401-21 DIAMOX SEQUELS CARDIOVASCULAR ANTIHYPERTENSIVE 1246432 ACETAZOLAMIDE SODIUM INJ STER PWD SDV 10ML 500MG/VL EACH INJ CARDINAL 39822-0190-01 DIAMOX INJ CARDIOVASCULAR ANTIHYPERTENSIVE 1242661 ACETAZOLAMIDE TABLETS 125MG 100/BT RX CARDINAL 51672-4022-01 DIAMOX TABS CARDIOVASCULAR ANTIHYPERTENSIVE 2770632 ACETAZOLAMIDE TABLETS 250MG 100/BT RX CARDINAL 51672-4023-01 DIAMOX TABS CARDIOVASCULAR ANTIHYPERTENSIVE 2770624 ACETIC ACID OTIC SOLUTION 2% 15ML/BT RX CARDINAL 60432-0741-15 VOSOL LIQUID EYE,EAR, NOSE OTICS 2770398 ACETIC ACID W/HC OTIC SOLUTION 2%/1% 10ML/BT RX CARDINAL 50383-0901-10 VOSOL HC LIQUID EYE,EAR, NOSE OTICS 2770113 ACETIC ACID/ALUM OTIC SOLUTION 2% 60ML/BT RX CARDINAL 24208-0615-77 DOMEBORO LIQUID EYE,EAR, NOSE OTICS 1029799 ACETONE HZ LIQUID 1GAL OTC HUMCO 00395-0019-28 ACETONE LIQUID INFECTION CONTROL MISC 1029716 ACETONE OD LIQUID 16OZ/BT OTC HUMCO 00395-0019-16 ACETONE LIQUID INFECTION CONTROL MISC 1192680 ACETYLCYSTEINE SDV INJ 30ML 200MG/ML 4/BX INJ FRESENIUS 63323-0963-30 ACETADOTE INJ NERVOUS SYSTEM EXPECTORANT, ANTITUSSIVE 1222867 ACETYLCYSTEINE SOLUTION 4ML 10% 25/BX RX FRESENIUS 63323-0695-04 MUCOMYST LIQUID NERVOUS SYSTEM EXPECTORANT, ANTITUSSIVE 1222865 ACETYLCYSTEINE SOLUTION 10ML 10% 3/BX RX FRESENIUS 63323-0693-10 MUCOMYST LIQUID NERVOUS SYSTEM EXPECTORANT, ANTITUSSIVE 1222866 ACETYLCYSTEINE SOLUTION 30ML 10% 3/BX RX FRESENIUS 63323-0691-30 MUCOMYST LIQUID NERVOUS SYSTEM EXPECTORANT, ANTITUSSIVE 1100478 ACETYLCYSTEINE SOLUTION 4ML 20% 25/BX RX AMERICAN REGENT 00517-7604-25 MUCOMYST LIQUID NERVOUS SYSTEM EXPECTORANT, ANTITUSSIVE 1222869 ACETYLCYSTEINE SOLUTION 10ML 20% 3/BX RX FRESENIUS 63323-0692-10 MUCOSIL LIQUID NERVOUS SYSTEM EXPECTORANT, ANTITUSSIVE 1077346 ACETYLCYSTEINE SOLUTION 30ML 20% 3/BX RX HOSPIRA 00409-3308-03 MUCOSIL LIQUID NERVOUS SYSTEM EXPECTORANT, ANTITUSSIVE 2770678 ACYCLOVIR CAPSULES 200MG 100/BT RX CARDINAL 00093-8940-01 ZOVIRAX CAPS ANTI-INFECTIVE ANTI-VIRAL 2771069 ACYCLOVIR SODIUM INJ SDV 10ML 50MG/ML 10/BX INJ CARDINAL 55150-0154-10 ZOVIRAX INJ ANTI-INFECTIVE ANTI-VIRAL 8408817 ACYCLOVIR SODIUM INJ SDV 20ML 50MG/ML 10/BX INJ FRESENIUS 63323-0325-20 ZOVIRAX INJ ANTI-INFECTIVE ANTI-VIRAL Page 1 of 50 HENRY SCHEIN GENERIC PORTFOLIO GENERIC TO BRAND CROSS REFERENCE ALPHA ORDER: GENERIC DESCRIPTION ALL PRODUCTS: as of 2/1/16 SCHEIN CONTR RX, ITEM GENERIC DESCRIPTION STRENGTH SIZE DRUG OTC, SUPPLIER NAME NDC BRAND COMPARE TO MAJOR SPECIALTY INDICATION NUMBER CLASS INJ 1236316 ACYCLOVIR TABLETS 400MG 100/BT RX TOP RX 31722-0777-01 ZOVIRAX TABS ANTI-INFECTIVE ANTI-VIRAL 1236723 ACYCLOVIR TABLETS 400MG 500/BT RX TOP RX 31722-0777-05 ZOVIRAX TABS ANTI-INFECTIVE ANTI-VIRAL 1236317 ACYCLOVIR TABLETS 800MG 100/BT RX TOP RX 31722-0778-01 ZOVIRAX TABS ANTI-INFECTIVE ANTI-VIRAL 1242313 ACYCLOVIR TABLETS 800MG 500/BT RX TOP RX 31722-0778-05 ZOVIRAX TABS ANTI-INFECTIVE ANTI-VIRAL 1210893 ADENOSINE (SCAN) INJ SDV GLASS 20ML 3MG/ML EACH INJ TEVA 00703-8776-01 ADENOSCAN INJ CARDIOVASCULAR IMAGING AGENT 1210894 ADENOSINE (SCAN) INJ SDV GLASS 30ML 3MG/ML EACH INJ TEVA 00703-8777-01 ADENOSCAN INJ CARDIOVASCULAR IMAGING AGENT 1238882 ADENOSINE INJ SDV 2ML 3MG/ML 10/BX INJ CARDINAL 17478-0542-02 ADENOCARD INJ CARDIOVASCULAR ANTIARRHYTHMIC 2450119 ADENOSINE INJ SDV 2ML 3MG/ML 25/BX INJ AKORN 17478-0542-25 ADENOCARD INJ CARDIOVASCULAR ANTIARRHYTHMIC 2480408 ADENOSINE INJ SDV 2ML 3MG/ML EACH INJ GIV 17478-0542-02 ADENOCARD INJ CARDIOVASCULAR ANTIARRHYTHMIC 1199133 ADENOSINE INJ SDV 4ML 3MG/ML 10/PK INJ SAGENT 25021-0301-04 ADENOCARD INJ CARDIOVASCULAR ANTIARRHYTHMIC 1218777 ADENOSINE INJ SYRINGE 4ML 3MG/ML 10/BX INJ SAGENT 25021-0301-68 ADENOCARD INJ CARDIOVASCULAR ANTIARRHYTHMIC 1245584 ADULT MULTI VITAMIN GUMMY 60/BT RX GERI-CARE ADULT MULTI VITAMIN GUMMY HBA VITAMINS VITAMIN DEFICIENCY 1161818 ALBUTEROL NEBULIZED SOLUTION STERILE 0.083% 25x3ML RX NEPHRON 00487-9501-25 PROVENTIL/VENTOLIN LIQUID NERVOUS SYSTEM RESPIRATORY AID 2770261 ALBUTEROL NEBULIZED SOLUTION STERILE 0.083% 30x3ML RX CARDINAL 00487-9501-03 PROVENTIL/VENTOLIN LIQUID NERVOUS SYSTEM RESPIRATORY AID 2770674 ALBUTEROL NEBULIZED SOLUTION STERILE 0.083% 60x3ML RX CARDINAL 00487-9501-60 PROVENTIL/VENTOLIN LIQUID NERVOUS SYSTEM RESPIRATORY AID 1161820 ALBUTEROL NEBULIZED SOLN STERILE INDIV WRAP 0.083% 30x3ML RX NEPHRON 00487-9501-01 PROVENTIL/VENTOLIN LIQUID NERVOUS SYSTEM RESPIRATORY AID 1154206 ALBUTEROL SULFATE INHALATION SOLUTION 0.5% 20ML/BT RX VALEANT 24208-0347-20 PROVENTIL/VENTOLIN LIQUID NERVOUS SYSTEM RESPIRATORY AID 1162130 ALBUTEROL NEBULIZED SOLUTION STERILE .042% 1.25MG 25/BX RX NEPHRON 00487-9904-25 ACCUNEB LIQUID NERVOUS SYSTEM RESPIRATORY AID 1093443 ALBUTEROL SULFATE INHALATION SOLUTION 0.63MG/3ML 25x3ML RX ACTAVIS 00591-3467-53 ACCUNEB LIQUID NERVOUS SYSTEM RESPIRATORY AID 1243827 ALBUTEROL SULFATE INHALATION SOLUTION 0.63MG/3ML 30x3ML RX RITEDOSE 76204-0200-01 ACCUNEB LIQUID NERVOUS SYSTEM RESPIRATORY AID 1164177 ALBUTEROL SULFATE INHALATION SOLUTION 1.25MG/3ML 30X3ML/BX RX NEPHRON 00487-9904-01 ACCUNEB LIQUID NERVOUS SYSTEM RESPIRATORY AID 1221950 ALBUTEROL SULFATE INHALATION SOLUTION 2.5MG/.5ML 30/BX RX NEPHRON 00487-9901-30 ACCUNEB LIQUID NERVOUS SYSTEM RESPIRATORY AID 2770349 ALBUTEROL SULFATE ORAL SYRUP 2MG/5ML 480ML/BT RX CARDINAL
Load more

Recommended publications
  • Standard X-Ray Diffraction Powder Patterns
    NBS MONOGRAPH 25 — SECTION 1 Standard X-ray Diffraction U.S. DEPARTMENT OF COMMERCE NATIONAL BUREAU OF STANDARDS THE NATIONAL BUREAU OF STANDARDS Functions and Activities The functions of the National Bureau of Standards are set forth in the Act of Congress, March 3, 1901, as amended by Congress in Public Law 619, 1950. These include the development and maintenance of the national standards of measurement and the provision of means and methods for making measurements consistent with these standards; the determination of physical constants and properties of materials; the development of methods and instruments for testing materials, devices, and structures; advisory services to government agencies on scien- tific and technical problems; invention and development of devices to serve special needs of the Government; and the development of standard practices, codes, and specifications. The work includes basic and applied research, development, engineering, instrumentation, testing, evaluation, calibration services, and various consultation and information services. Research projects are also performed for other government agencies when the work relates to and supplements the basic program of the Bureau or when the Bureau's unique competence is required. The scope of activities is suggested by the listing of divisions and sections on the inside of the back cover. Publications The results of the Bureau's research are published either in the Bureau's own series of publications or in the journals of professional and scientific societies. The Bureau itself publishes three periodicals available from the Government Printing Office: The Journal of Research, published in four separate sections, presents complete scientific and technical papers; the Technical News Bulletin presents summary and preliminary reports on work in progress; and Basic Radio Propagation Predictions provides data for determining the best frequencies to use for radio communications throughout the world.
    [Show full text]
  • Chemistry: the Molecular Nature of Matter and Change
    REVISED CONFIRMING PAGES The Components of Matter 2.1 Elements, Compounds, and 2.5 The Atomic Theory Today 2.8 Formula, Name, and Mass of Mixtures: An Atomic Overview Structure of the Atom a Compound 2.2 The Observations That Led to Atomic Number, Mass Number, and Binary Ionic Compounds an Atomic View of Matter Atomic Symbol Compounds That Contain Polyatomic Mass Conservation Isotopes Ions Definite Composition Atomic Masses of the Elements Acid Names from Anion Names Multiple Proportions 2.6 Elements: A First Look at the Binary Covalent Compounds The Simplest Organic Compounds: Dalton’s Atomic Theory Periodic Table 2.3 Straight-Chain Alkanes Postulates of the Atomic Theory Organization of the Periodic Table Masses from a Chemical Formula How the Atomic Theory Explains Classifying the Elements Representing Molecules with a the Mass Laws Compounds: An Introduction 2.7 Formula and a Model to Bonding 2.4 The Observations That Led to Mixtures: Classification and the Nuclear Atom Model The Formation of Ionic Compounds 2.9 Separation Discovery of the Electron and The Formation of Covalent An Overview of the Components of Its Properties Compounds Matter Discovery of the Atomic Nucleus (a) (b) (right) ©Rudy Umans/Shutterstock IN THIS CHAPTER . We examine the properties and composition of matter on the macroscopic and atomic scales. By the end of this chapter, you should be able to • Relate the three types of matter—elements or elementary substances, compounds, and mixtures—to the simple chemical entities that they comprise—atoms, ions, and molecules;
    [Show full text]
  • Cosmetic Ingredient Hotlist - Canada.Ca
    9/25/2018 Cosmetic Ingredient Hotlist - Canada.ca Home Health Product safety Consumer Product Safety Cosmetics Cosmetic Ingredient Hotlist: Prohibited and Restricted Ingredients Cosmetic Ingredient Hotlist For assistance on the Ingredient Hotlist, please refer to "How to read the Cosmetic Ingredient Hotlist" 2018 List of Ingredients that are Prohibited for Use in Cosmetic Products List of Ingredients that are Restricted for Use in Cosmetic Products List of Ingredients that are Prohibited for Use in Cosmetic Products # A B C D E F G H I J L M N O P R S T U V W X Y Z CAS (Chemical Abstracts Service) (including but not limited to) Synonyms and Related Compounds Ingredient 1 (including but not limited to) 2 1,2-Epoxybutane 106-88-7 1,3-Butadiene 106-99-0 1,3-Dimethylpentylamine and its salts 105-41-9 11-α-Hydroxypregn-4-ene-3,20-dione and its esters 80-75-1 1- and 2-Naphthylamines and their salts 134-32-7; 91-59-8 1-Butyl-3-(N-crotonoylsulfanilyl) urea 52964-42-8 2-Butenamide, N-[4- [[[(butylamino)carbonyl]amino]sulfonyl]phenyl]-; Crotonoylcarbutamide; Crotulin 1-Methoxy-2,4-diaminobenzene and its salts 615-05-4 2,4-diaminoanisole; Cl 76050 1-Methoxy-2,5-diaminobenzene and their salts 5307-02-8 2,5-diaminoanisole 2-(4-Allyl-2-methoxyphenoxy)-N,N-diethylacetamide and its salts 305-13-5 Estil 2-(4-Methoxybenzyl-N-(2-pyridyl)amino) ethyldimethylamine maleate 59-33-6 2,3,7,8-Tetrachlorodibenzo-p-dioxin 1746-01-6 2,3-Dichloro-2-methylbutane 507-45-9 Amylene dichloride 2,4-Diaminophenylethanol and its salts 14572-93-1 1 Cells in this column are left blank when the substance does not have a known CAS.
    [Show full text]
  • HEALTH PROFESSIONAL CONSULTANT to a PHARMACEUTICAL COMPANY V JOHNSON & JOHNSON Nicorette Advertisement
    CASE AUTH/2930/1/17 HEALTH PROFESSIONAL CONSULTANT TO A PHARMACEUTICAL COMPANY v JOHNSON & JOHNSON Nicorette advertisement A complaint was received in a private capacity that the implication was that the statement in from a health professional who stated that he/ question related to a feature of Nicorette, that the she worked as a consultant to a pharmaceutical product itself had incredible features and/or that company. health professionals would be doing something incredible by prescribing it. The implication was The complaint concerned an online advertisement misleading and exaggerated and breaches of the for Nicorette (nicotine) issued by Johnson & Code ruled. Johnson published in Pulse. The complainant stated at the time of submitting The complainant provided a screenshot of a the complaint that he/she was a health professional banner advertisement. It included ‘Nicorette. Do who worked as a consultant to Novartis. It had something incredible’. The complainant did not previously been decided, following consideration believe that the word ‘incredible’ was suitable. This by the then Code of Practice Committee and the information did not appear to be balanced and was ABPI Board of Management, that private complaints exaggerated. The claim was taken directly from from pharmaceutical company employees had material aimed at the general public and it appeared to be accepted. To avoid this becoming a means that Johnson & Johnson had not undertaken a of circumventing the normal procedures for sufficiently robust review when translating to intercompany complaints, the employing company promotion aimed at health professionals. would be named in the report. The complainant would be advised that this would happen and be The detailed response from Johnson & Johnson is given an opportunity to withdraw the complaint.
    [Show full text]
  • Ed 091 175 Title Institution Pub Date Available From
    DOCUMENT RESUME ED 091 175 SE 017 514 TITLE Science: Grade 7. Curriculum Bulletin, 1971-72 Series, No.2. INSTITUTION New York City Board of Education, Brooklyn, N.Y. Bureau of Curriculum Development. PUB DATE 71 NOTE 330p. AVAILABLE FROM New York Board of Education, Publications Sales Office, 110 Livingston Street, Brooklyn, New York 11201 ($5.00) EDRS PRICE MF-$0.75 HC Not Available from EDRS. PLUS POSTAGE DESCRIPTORS Biology; *Curriculum Guides; Earth Science; General Science; Grade 7; Physical Sciences; *Science Activities; Science Education; *Secondary School Science; *Teaching Guides IDENTIFIERS New York City ABSTRACT This book is a curriculum guide for seventh-grade general science. It contains four units of chemistry, physics, biology, and earth science. Each unit is divided into sections covering major concepts. Each section contains science activitiesand contains explanations of objectives and implementation of the lesson. At the end of each section are review exercises, research topics, and resource materials. Also following each unit is a suggested unit examination. (MR) 4f Ba. o fE&. AIIn U S DEPARTYENT OF HEALTH EDUCATION I VSElf ARE NATIONAL INSTITUTE Of EDUCATION S DOCS'E".. RE EN ,EPq: D,cEO Exac , AE'Ef", 'HE.ERSONCQC',"0..}A.:%C., A' ,E PO %c E A 4 1, *A -D DO 4.2' A .NA' Cba " Fr JCA E. E A 4 r BUREAU OF CURRICULUM DEVELOPMENT BOAPP OF EIrUCATION CITY OF NEW YORK Permission to re-rc.'tIce this cc "''k has been granted to ther.eluo.1..nAt Recources Ir..--.'onCenter (ERIC) owl to the organization operating undercentract with the U,S.
    [Show full text]
  • Nicorette Invisipatch 25 Mg/16 H Transdermal Patch
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Nicorette invisipatch 25 mg/16 h transdermal patch Nicorette invisipatch 15 mg/16 h transdermal patch Nicorette invisipatch 10 mg/16 h transdermal patch 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each transdermal patch contains nicotine 1.75 mg/cm2. Nicorette invisipatch 25 mg/16 h, of 22.5 cm2 size contains nicotine 39.37 mg and releases nicotine 25 mg /16 hours Nicorette invisipatch 15 mg/16 h, of 13.5 cm2 size contains nicotine 23.62 mg and releases nicotine 15 mg /16 hours Nicorette invisipatch 10 mg/16 h, of 9.0 cm2 size contains nicotine 15.75 mg and releases nicotine 10 mg /16 hours For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Transdermal patch Beige, semi-transparent, rectangular patch with rounded edges and light-brown “Nicorette” printing, is placed on an easily removable layer coated with aluminium and silicon and is formed by nicotine layer and adhesive acrylate layer. 4. CLINICAL PARTICULARS 4.1. Therapeutic indication Nicorette invisipatch is to be used for the treatment of tobacco dependence in adults by relief of nicotine withdrawal symptoms, including cravings, during a quit attempt. Permanent cessation of tobacco use is the eventual objective. Nicorette invisipatch is indicated in adults. Nicorette invisipatch should preferably be used in conjunction with a behavioral support program. 4.2. Posology and method of administration Posology Subjects should stop smoking completely during the course of treatment with Nicorette invisipatch. Administration of nicotine should be stopped immediately if any symptoms of overdose listed in Section 4.9 occur.
    [Show full text]
  • Over-The-Counter Mail Order Program 1-866-768-8490 As a Superior
    Over-the-Counter Mail Order Program 1-866-768-8490 As a Superior value-added service, STAR+PLUS and STAR Health members can get $30 in items every 3 months (90 days). STAR members can get $25 in items every 3 months (90 days). No prescription is needed. To order, please call 1-866-768-8490. Have your Superior ID card ready when you call. Your order will be mailed to your home in 5-10 days. Please use these items only as directed. If you have questions about safe use of any of these items, talk to your doctor. Item Description Compare to: Price Item Description Compare to: Price Analgesics Eye Care 1 Ibuprofen 200mg tab Motrin IB $6 31 Tetrahydrozoline drops Visine $4 2 Naproxen sod 220mg tab Aleve $9 61 Lubricating eye drops Refresh Tears $7 3 Aspirin 325mg tab Bayer Aspirin $5 First Aid Creams/Ointments 4 Aspirin ec 325 mg tab Ecotrin $6 32 Calamine lotion Calamine Lotion $4 5 Aspirin ec 81 mg Halfprin $5 33 Hydrocortisone !5 cream Cort-Aid $4 6 Acetaminophen 500mg tab Tylenol Extra Str $6 34 Triple antibiotic ointment Neosporin $5 7 Mentholated ointment Ben Gay $6 60 Medicated lip balm Carmex $3 Antacids First Aid Supplies 8 Simethicone 80mg tab Mylanta Anti-Gas $6 35 Athletic bandage Ace Bandage $7 9 Calc carb 500mg chewable TUMS $6 36 Adhesive tape First-Aid Tape $3 10 Famotidine 10mg tab Pepcid AC $9 37 Band-aids Band-Aids $4 Antidiarrheals 38 Carbamide peroxide Debrox Drops $4 11 Loperamide 2mg cap Imodium $5 39 Gauze pads Gauze Pads $3 12 Bismuth mixture Pepto-Bismol $5 40 Cotton swab Q-Tips $4 Antifungals 41 Oral thermometer Thermometer
    [Show full text]
  • FDA Listing of Authorized Generics As of July 1, 2021
    FDA Listing of Authorized Generics as of July 1, 2021 Note: This list of authorized generic drugs (AGs) was created from a manual review of FDA’s database of annual reports submitted to the FDA since January 1, 1999 by sponsors of new drug applications (NDAs). Because the annual reports seldom indicate the date an AG initially entered the market, the column headed “Date Authorized Generic Entered Market” reflects the period covered by the annual report in which the AG was first reported. Subsequent marketing dates by the same firm or other firms are not included in this listing. As noted, in many cases FDA does not have information on whether the AG is still marketed and, if not still marketed, the date marketing ceased. Although attempts have been made to ensure that this list is as accurate as possible, given the volume of d ata reviewed and the possibility of database limitations or errors, users of this list are cautioned to independently verify the information on the list. We welcome comments on and suggested changes (e.g., additions and deletions) to the list, but the list may include only information that is included in an annual report. Please send suggested changes to the list, along with any supporting documentation to: [email protected] A B C D E F G H I J K L M N O P Q R S T U V X Y Z NDA Applicant Date Authorized Generic Proprietary Name Dosage Form Strength Name Entered the Market 1 ACANYA Gel 1.2% / 2.5% Bausch Health 07/2018 Americas, Inc.
    [Show full text]
  • Lna 2006 Profiles J.Qxp
    1 | Advertising Age | June 26, 2006 SpecialSpecial ReportReport:100 Profiles LEADING NATIONAL ADVERTISERSSupplement SUPPLEMENT June 26, 2006 100 LEADING NATIONAL ADVERTISERS Profiles of the top 100 U.S. marketers in this 51st annual ranking INSIDE TOP 100 RANKING COMPANY PROFILES SPONSORED BY The nation’s leading marketers Lead marketing personnel, ranked by U.S. advertising brands, agencies, agency expenditures for 2005. contacts, as well as advertising Includes data from TNS Media spending by media and brand, Intelligence and Ad Age’s sales, earnings and more for proprietary estimates of the country’s 100 largest unmeasured spending. PAGE 8 advertisers PAGE 10 This document, and information contained therein, is the copyrighted property of Crain Communications Inc. and The Ad Age Group (© Copyright 2006) and is for your personal, non-commercial use only. You may not reproduce, display on a website, distribute, sell or republish this document, or information contained therein, without prior written consent of The Ad Age Group. Are proud to connect you with the leading CMOs See all the interviews at adage.com/point LAUNCHING JUNE 28 © 2006 Crain Communications Inc. www.adage.com 3 | Advertising Age | June 26, 2006 Special Report 100 LEADING NATIONAL ADVERTISERS SUPPLEMENT ABOUT THIS PROFILE EDITION THE 51ST ANNUAL 100 Leading National the Top 100 ($40.13 billion) and for all measured spending in 18 national media, Advertisers Report crowned acquisition- advertisers ($122.79 billion) in the U.S. Yellow Pages Association contributed ladened Procter & Gamble Co. as the top U.S. ad spending by ad category: This spending in Yellow Pages and TNS Marx leader, passing previous kingpen General chart (Page 6) breaks out 18 measured Promotion Intelligence provided free- Motors Corp.
    [Show full text]
  • Lifescan Ethicon
    LouiseLouise MehrotraMehrotra ViceVice PresidentPresident InvestorInvestor RelationsRelations ““SafeSafe HarborHarbor”” StatementStatement This presentation may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company’s expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2006. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from the Company. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments. WilliamWilliam C.C. WeldonWeldon ChairmanChairman ofof thethe BoardBoard && ChiefChief ExecutiveExecutive OfficerOfficer TodayToday’’ss AgendaAgenda
    [Show full text]
  • 1. Preparation of Sulfide Powder (1) Mgs Powder Powder Of
    Transactions of the Japan Institute of Metals, Vol. 25, No. 10 (1984), pp. 692 to 697 Ionic and Positive Hole Conductivities of Solid Magnesium and Strontium Sulfides* By Hiroaki Nakamura**, Youichi Ogawa**, Koki Gunji† and Akira Kasahara** The electrical conductivity of MgS and SrS disks carefully prepared to avoid any contamination has been measured at temperatures from 973 to 1223 K and in the Ps2 range from 10-10 to 104 Pa. Because the conductivity was independent of sulfur pressure in the low sulfer pressure range, it was concluded that MgS and SrS may be ionic conductors. The specific conductivity can be expressed as follows; and the apparent activation energy for the conduction of MgS and SrS is 218 kJ/mol and 180 kJ/mol, respectively. However, in the high sulfur pressure range, the specific conductivity of both sulfides increases with an increase in sulfur pressure, suggesting the positive hole conduction. (ReceivedApril 23, 1984) Keywords: magnesium sulfide, strontium sulfide, electrical conductivity, sulfur pressure, ionic conduction, hole conduction, activation energy, alternating current bridge, polarization and strontium were very carefully prepared . Introduction and served for the measurement of electrical conductivity in a wide range of sulfur partial Sulfides have been paid attention to as solid pressure. Potentiostatic polarization was also electrolyte. The physico-chemical properties of carried out to determine the mechanism of con- most of them have not well been studied, com- duction. pared with oxides and halides in actual use as electrolytes. Ⅱ. Experimental Method In this study the electrical conductivity of 1. Preparation of sulfide powder the sulfides of magnesium (MgS) and stron- tium (SrS), which are the same alkaline earths (1) MgS powder as calcium(1), was measured in order to seek for Powder of MgS was prepared by reacting the potential use of them as solid electrolytes.
    [Show full text]
  • Nicorette Invisipatch 25 Mg/16 H Transdermal Patch Nicorette Invisipatch 15 Mg/16 H Transdermal Patch Nicorette Invisipatch 10 Mg/16 H Transdermal Patch
    Package leaflet: Information for the user Nicorette invisipatch 25 mg/16 h transdermal patch Nicorette invisipatch 15 mg/16 h transdermal patch Nicorette invisipatch 10 mg/16 h transdermal patch (nicotine) Read all of this leaflet carefully before you start using this medicine because it contains important information for you. Always use this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you. - Keep this leaflet. You may need to read it again. - Ask your pharmacist if you need more information or advice. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. - You must talk to a doctor if you have not been able to stop smoking after 6 months of treatment with Nicorette Invisipatch. What is in this leaflet: 1. What Nicorette invisipatch is and what it is used for 2. What you need to know before you use Nicorette invisipatch 3. How to use Nicorette invisipatch 4. Possible side effects 5 How to store Nicorette invisipatch 6. Contents of the pack and other information 1. What Nicorette invisipatch is and what it is used for Nicorette invisipatch is a medicinal product helping you to stop smoking. Nicorette invisipatch is used to treat tobacco dependence, to relieve cravings for smoking (nicotine) and nicotine withdrawal symptoms, which helps the motivated smokers to stop smoking. When you stop smoking and providing your body with nicotine from tobacco, you can experience unpleasant feelings called withdrawal symptoms. By using Nicorette invisipatch you can prevent or reduce these unpleasant feelings - by using Nicorette invisipatch patches you continue to provide your body with small amount of nicotine in its pure form, which does not bring about health risks associated with smoking.
    [Show full text]